Oncolytics receives FDA Fast Track designation for pelareorep

Oncolytics Biotech (ONCY) announced that the U.S. FDA has granted Fast Track designation to pelareorep in combination with Roche’s (RHHBY) anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma. This represents pelareorep’s second FDA Fast Track designation.